| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | lapatinib | FIMM | pan-cancer | AAC | -0.089 | 0.6 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.6 |
| mRNA | Cyclopamine | FIMM | pan-cancer | AAC | -0.079 | 0.6 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |